QC
XGN icon

Quadrature Capital’s Exagen XGN Stock Holding History

Quadrature Capital’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,414
Closed -$125K – 1709
2025
Q3 		$125K Sell
11,414
-19,641
-63% -$174K ﹤0.01% 853
2025
Q2 		$217K Buy
+31,055
New +$189K ﹤0.01% 794

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Quadrature Capital's XGN Position: Q4 2025 in Review

Quadrature Capital sold out of Exagen (XGN) in Q4 2025, closing a stake of 11,414 shares — an estimated $125K sold.

Quadrature Capital first reported a position in XGN in Q2 2025 and held it in 2 quarters. The position peaked at $217K in Q2 2025. 80 funds tracked by Wall St. Rank hold XGN as of Q4 2025.

  • Quadrature Capital reported no remaining Exagen position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 11,414 Exagen shares in Q4 2025, an estimated $125K.
  • Quadrature Capital first reported a position in Exagen in Q2 2025 and held it in 2 quarters.
  • Quadrature Capital's Exagen position peaked at $217K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Exagen as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.